Yep. But big BPs have a bigger hole in their pocket. Also, I think NWBO have a lot of iron in the fire. That is the reason they are focusing to bring EDEN into commercialization.
There are also mid to smaller companies making ctla ci’s, such as biontech.
True but only Bristol Myers Squibb (BMS) and AstraZeneca produce FDA-approved CTLA-4 Blockade in Tumor. I find it highly unlikely that NWBO would pursue combi trials with UNapproved CTLA-4 while DCVAXL is MHRA approved